Royalty Pharma plc (RPRX) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001802768 · SEC filings checked Oct 18, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 5, 2026 | $674.1M | $17.9M | $0.04 | Filing |
| Mar 31, 2026 | May 6, 2026 | $630.6M | $294.7M | $0.67 | Filing |
| Dec 31, 2025 | Feb 11, 2026 | $622.0M | $211.2M | $0.49 | Filing |
| Sep 30, 2025 | Nov 5, 2025 | $609.3M | $288.2M | $0.67 | Filing |
| Jun 30, 2025 | Aug 6, 2025 | $578.7M | $32.2M | $0.07 | Filing |
| Mar 31, 2025 | May 8, 2025 | $568.2M | $239.3M | $0.55 | Filing |
| Dec 31, 2024 | Jan 10, 2025 | $593.6M | $208.2M | $0.46 | Filing |
| Sep 30, 2024 | Nov 6, 2024 | $564.7M | $544.0M | $1.21 | Filing |
What would Royalty Pharma plc have to report for its valuation to change?
At $62.15, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about 23.2% a year, to $5.31. On that path the next quarter needs diluted EPS near $0.83, against $0.67 in the quarter ended Sep 30, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | 23.2% | 23.2% |
| EPS needed in final year | $5.31 | $5.31 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. RPRX goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.